Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia

Authors

  • Beatriz Carvalho Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Paulo Freitas-Costa Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • João Pinheiro-Costa Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Manuel Falcão Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Ângela Carneiro Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Fernando Falcão-Reis Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

DOI:

https://doi.org/10.20344/amp.2038

Abstract

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.
Material and Methods: In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment.
Results: The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9μm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001).
Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

Downloads

Author Biographies

Beatriz Carvalho, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Paulo Freitas-Costa, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

João Pinheiro-Costa, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Manuel Falcão, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Ângela Carneiro, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Fernando Falcão-Reis, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Published

2014-01-08

How to Cite

1.
Carvalho B, Freitas-Costa P, Pinheiro-Costa J, Falcão M, Carneiro Ângela, Falcão-Reis F. Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia. Acta Med Port [Internet]. 2014 Jan. 8 [cited 2025 Apr. 3];27(1):49-58. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/2038